SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Kymera Therapeutics Posts Q3 Loss of $1.32 Per Share

Kymera Therapeutics reported a Q3 loss of $1.32 per share, versus the FactSet estimate of a $1.26 loss per share.

KYMR
SquawkNews Desk 1 updates Updated Oct 29, 2026, 11:21 AM UTC

Story updates

11:21:41 AM UTC
SquawkNews
Kymera Therapeutics reported third-quarter 2026 revenue of $0 compared with $2.8M a year earlier, and a net loss of $132M, or $(1.32) per diluted share, versus a net loss of $82.2M, or $(0.94) per share, in the prior-year quarter.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Kymera Th…

Related stories

Marcus Corp Reports Quarterly Results Through September 30 Marcus Corp reported results for the quarter ended September 30; no figures were provided. M impact | EQUITY | Oct 29, 2026, 04:37 PM UTC Marconi Technologies Awarded U.S. Army Production Order for TRILOS Marconi Technologies was awarded a production order to modernize TRILOS by the U.S. Army. L impact | EQUITY | Oct 29, 2026, 04:35 PM UTC Godrej Consumer Q2 Revenue Rises 19% Year on Year Godrej Consumer Products reported higher revenue for the September quarter of fiscal 2027. Pricing actions and cost savings helped offset rising input costs. M impact | EQUITY | Oct 29, 2026, 04:35 PM UTC Higher Freight Rates Add $5.4 Billion to Shell's Debt Shell said freight rates added $5.4 billion to shipping lease costs in the third quarter versus the previous three months, feeding into net debt. TotalEnergies said freight rates c M impact | EQUITY | Oct 29, 2026, 04:35 PM UTC Poundland Files Notice of Intention to Appoint Administrators M impact | EQUITY | Oct 29, 2026, 04:34 PM UTC Summi Group Delays Annual Results Publication Due to Audit Procedures M impact | EQUITY | Oct 29, 2026, 04:34 PM UTC